bluebird bio, Inc. (BLUE) analyst actions
Rating and price-target actions on BLUE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BLUE overview →
1 measured BLUE analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025 | Press release | -0.87% | -1.44% |
Keep exploring
More BLUE: earnings → · SEC filings → · BLUE overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cerecor, Inc (CERC) | 795 | -0.03% | 43% |
| Second Sight Medical Products, Inc. (EYES) | 788 | -0.56% | 34% |
| Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) | 784 | 0.00% | 45% |
| Heat Biologics, Inc. (HTBX) | 781 | -0.40% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.